Publications by authors named "Kurt Pike"

Claim this Profile
A
Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase.
Nicola Colclough, Alexandra L Orton, Scott Martin, Martin Wild, Venkatesh Pilla Reddy, Kurt G Pike

Drug Metab Dispos· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
Kurt G Pike, Thomas A Hunt, Bernard Barlaam, David Benstead, Elaine Cadogan

J Med Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS with Demonstrable CNS Penetration.
Jason G Kettle, Sharan K Bagal, Derek Barratt, Michael S Bodnarchuk, Scott Boyd, Kurt Pike

J Med Chem· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and optimization of a novel series of selective PIP5K inhibitors.
David M Andrews, Sharon Cartic, Sabina Cosulich, Nullin Divecha, Paul Faulder, Kurt G Pike

Bioorg Med Chem· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
Sharan K Bagal, Clare Gregson, Daniel H O' Donovan, Kurt G Pike, Andrew Bloecher, Andrew Pike

J Med Chem· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
Bernard Barlaam, Chris De Savi, Allan Dishington, Lisa Drew, Andrew D Ferguson, Kurt G Pike

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
Daniel H O' Donovan, Clare Gregson, Martin J Packer, Ryan Greenwood, Kurt G Pike

Bioorg Med Chem Lett· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
Bernard Barlaam, Robert Casella, Justin Cidado, Calum Cook, Chris De Savi, Andy Pike, Kurt G Pike

J Med Chem· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Lucy C Riches, Antonio G Trinidad, Gareth Hughes, Gemma N Jones, Adina M Hughes, Kurt G Pike

Mol Cancer Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.
Jeremy Karlin, Jasmine Allen, Syed F Ahmad, Gareth Hughes, Victoria Sheridan, Kurt G Pike

Mol Cancer Ther· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.
Bernard Barlaam, Elaine Cadogan, Andrew Campbell, Nicola Colclough, Allan Dishington, Kurt G Pike

ACS Med Chem Lett· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
Sébastien L Degorce, Bernard Barlaam, Elaine Cadogan, Allan Dishington, Richard Ducray, Kurt G Pike

J Med Chem· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Stephen T Durant, Li Zheng, Yingchun Wang, Kan Chen, Lingli Zhang, Kurt G Pike

Sci Adv· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
Kurt G Pike, Bernard Barlaam, Elaine Cadogan, Andrew Campbell, Yingxue Chen

J Med Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.
Isabel Morgado-Palacin, Amanda Day, Matilde Murga, Vanesa Lafarga, Marta Elena Anton, Kurt G Pike

Sci Signal· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9.
Carl S Rye, Nicola E A Chessum, Scott Lamont, Kurt G Pike, Paul Faulder

Medchemcomm· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
Sébastien L Degorce, Bernard Barlaam, Elaine Cadogan, Allan Dishington, Richard Ducray, Kurt G Pike

J Med Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Sylvie M Guichard, Jon Curwen, Teeru Bihani, Celina M D'Cruz, James W T Yates, Kurt G Pike

Mol Cancer Ther· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2.
Kurt G Pike, Jeff Morris, Linette Ruston, Sarah L Pass, Ryan Greenwood

J Med Chem· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.
Jeffrey W Johannes, Lynsie Almeida, Bernard Barlaam, P Ann Boriack-Sjodin, Robert Casella, Kurt G Pike

ACS Med Chem Lett· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
Kurt G Pike, Karine Malagu, Marc G Hummersone, Keith A Menear, Heather M E Duggan

Bioorg Med Chem Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.
M Raymond V Finlay, David Buttar, Susan E Critchlow, Allan P Dishington, Shaun M Fillery, Kurt G Pike

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Dearg S Brown, John G Cumming, Paul Bethel, Jonathan Finlayson, Stefan Gerhardt, Kurt G Pike

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A concise total synthesis of deoxyschizandrin and exploration of its antiproliferative effects and those of structurally related derivatives.
Shaojun Zheng, Sarah J Aves, Luca Laraia, Warren R J D Galloway, Kurt G Pike

Chemistry· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.
Kurt G Pike, Joanne V Allen, Peter W R Caulkett, David S Clarke, Craig S Donald

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis